ICD THERAPEUTICS

icd-therapeutics-logo

ICD Therapeutics is a privately held MacroDel biologics-delivery platform developer.

#More

ICD THERAPEUTICS

Industry:
Biotechnology Therapeutics

Address:
Berlin, Berlin, Germany

Country:
Germany

Status:
Active

Contact:
+49 (0)30.890 49 74

Email Addresses:
[email protected]


More informations about "ICD Therapeutics"

ICD Therapeutics Company Profile 2024: Valuation, Investors ...

ICD Therapeutics General Information Description. Developer of MacroDel technology intended to block protein-protein interactions inside cancer cells. The company's platform develops …See details»

Boehringer Ingelheim Enhances Oncology R&D | BI US

Ingelheim, Germany and Berlin, Germany – 29 March 2019 – Boehringer Ingelheim today announced that it acquired ICD Therapeutics. The acquisition includes rights to ICD’s …See details»

Boehringer Ingelheim acquires ICD Therapeutics - 2019-03-29 ...

Mar 29, 2019 ICD Therapeutics ICD Therapeutics is a privately held MacroDel biologics-delivery platform developer. Acquiring Organization: Boehringer Ingelheim Boehringer Ingelheim is a …See details»

ICD Therapeutics - Products, Competitors, Financials, Employees ...

ICD Therapeutics has developed a biologics-delivery platform that exploits transporter proteins in the cell membrane to deliver such drug candidates inside tumor cells. Use the CB Insights …See details»

Boehringer Ingelheim enhances oncology R&D with novel …

Apr 5, 2019 Boehringer Ingelheim announced that it acquired ICD Therapeutics. The acquisition includes rights to ICD's innovative MacroDel biologics-delivery platform. Boehringer Ingelheim …See details»

Boehringer Ingelheim Enhances Oncology R&D with Novel …

Mar 29, 2019 Boehringer Ingelheim will employ this platform for the development of novel therapeutics in collaboration with nanoPET Pharma GmbH, a former shareholder of ICD …See details»

Boehringer Ingelheim Enhances Oncology R&D with Novel

Mar 29, 2019 INGELHEIM, Germany & BERLIN--(BUSINESS WIRE)-- Boehringer Ingelheim today announced that it acquired ICD Therapeutics.The acquisition includes rights to ICD’s …See details»

ICD Therapeutics - Crunchbase

ICD Therapeutics, Cincera Therapeutics, and Acousia Therapeutics operate in the biotechnology sector. Cincera Therapeutics and Acousia Therapeutics focus on developing biotech solutions …See details»

Boehringer Ingelheim acquires ICD Therapeutics

Boehringer Ingelheim has announced€that it acquired ICD Therapeutics. The acquisition includes rights to ICD’s innovative MacroDel biologics-delivery platform. Boehringer Ingelheim will …See details»

Boehringer Ingelheim acquires ICD Therapeutics

The acquisition includes rights to ICD’s innovative MacroDel biologics-d. Products Suppliers Sourcing Requests ... Industry Insights > Market News > Boehringer Ingelheim acquires ICD …See details»

Boehringer acquires ICD to ease biologic delivery

Apr 15, 2019 Boehringer acquires rights to ICD Therapeutics and its biologics-delivery platform for the development of oncology and immune oncology compounds. Using the acquired …See details»

ICD-Therapeutics GmbH Company Profile - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for ICD-Therapeutics GmbH of Ingelheim am Rhein, Rheinland-Pfalz. Get the latest business insights …See details»

PTC Therapeutics Enters into a Global License and Collaboration ...

2 days ago - PTC to receive $1.0B in cash at closing - - PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones - - PTC to share profits in the U.S. and tiered …See details»

Harnessing immunogenic cell death for cancer - Nature

By focusing on immunogenic cell death (ICD) as a complementary mechanism to existing cancer immunotherapy strategies, Phosplatin Therapeutics is building a global network of …See details»

ICH Official web site : ICH

Jun 27, 2023 Press Release New collaboration between WHO International Classification of Diseases (ICD) and MedDRA launched 27 June 2023 Today the World Health Organization …See details»

Nanomedicine to aid immunogenic cell death (ICD)-based …

Mar 28, 2024 Immunogenic cell death (ICD) is emerging as a key component of antitumor therapy that harnesses the immune system of the patient to combat cancer. In recent years, …See details»

ICD Therapeutics - Tech Stack, Apps, Patents & Trademarks

Organization. ICD Therapeutics . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. Patents and Trademarks by IPqwery. Edit Patents and …See details»

Targeting immunogenic cell stress and death for cancer therapy

Apr 15, 2024 Immunogenic cell death (ICD), which results from insufficient cellular adaptation to specific stressors, occupies a central position in the development of novel anticancer …See details»

Immunogenic cell death—the next frontier in cancer …

Phosplatin Therapeutics is harnessing immunogenic cell death (ICD) as an alternative mechanism to existing cancer immunotherapy strategies. PT-112, Phosplatin’s lead ICD inducer, is in …See details»

PTC Therapeutics Enters into a Global License and Collaboration ...

3 days ago PTC Therapeutics, "Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients," news …See details»